Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06207032 · ClinicalTrials.gov registry record
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
A clinical trial of Cancer, sponsored by Tempus AI.
- Recruiting
- Registry status
- 500
- Enrollment target
- 20
- Study locations
NCT06207032 is a study of Cancer that is actively recruiting participants, run by Tempus AI. The registered enrollment target is 500 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT06207032, a study of Cancer, is actively recruiting participants, sponsored by Tempus AI.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.
Conditions Studied
Study Locations (20)
Illinois
- Southern Illinois Healthcare - Carterville
- Hope and Healing Cancer Services - Hinsdale
- Cancer Care Specialists of Illinois - O'Fallon
- Illinois Cancer Care - Peoria
- Northwest Oncology and Hematology - Rolling Meadows
Missouri
- Hannibal Regional Healthcare System, Inc. - Hannibal
- Lake Regional Health - Osage Beach
- Mosaic Life Care - Saint Joseph
- Oncology Hematology Associates - Springfield
Georgia
- Morehouse - Atlanta
- Piedmont Healthcare - Atlanta
Indiana
- Fort Wayne - Fort Wayne
- Goshen Center for Cancer Care - Goshen
Alabama
- Alabama Oncology - Birmingham
California
- PIH Health Whittier Hospital & PIH Health Physicians - Whittier
Connecticut
- Eastern CT and Hematology and Oncology Associates - Norwich
Florida
- Cancer Specialists of North Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-06-26 |
| Est. Completion | 2029-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06207032
The ClinicalTrials.gov registry entry for NCT06207032 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (86% lower). The listed sponsor is Tempus AI, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06207032 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Illinois, Missouri, Georgia.
Frequently Asked Questions
What is clinical trial NCT06207032 about?
NCT06207032 is a clinical study titled "TEMPUS ARIES: A Biobank Registry Platform Study in Oncology". This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.
What is the current status of trial NCT06207032?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-06-26. Estimated completion is 2029-06-01.
What conditions does trial NCT06207032 study?
This clinical trial studies the following conditions: Cancer.
Who is sponsoring clinical trial NCT06207032?
This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06207032 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.